B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice

Blood

Volumn 117, Issue 7, 2011, Pages 2227-2236

  Chu, Yuanyuan ^a   Vahl, J Christoph ^a   Kumar, Dilip ^a   Heger, Klaus ^a   Bertossi, Arianna ^a   Wójtowicz, Edyta ^a   Soberon, Valeria ^a   Schenten, Dominik ^b   Mack, Brigitte ^c   Reutelshófer, Miriam ^d   Beyaert, Rudi ^e   Amann, Kerstin ^d   Van Loo, Geert ^e   Schmidt Supprian, Marc ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN;

AGED; ANIMAL CELL; ARTICLE; AUTOIMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE MUTATION; HUMAN; MARGINAL ZONE LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REGULATORY T LYMPHOCYTE; SPLENOMEGALY;

EID: 79951833148     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-306019     Document Type: Article

References (41)

1. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8(1):22-33.
2. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell. 2007;130(1):25-35. (Pubitemid 47031326)
3. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251-262. (Pubitemid 40488631)
4. Graham RR, Cotsapas C, Davies L, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet. 2008;40(9):1059-1061.
5. Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet. 2008;40(9):1062-1064.
6. Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet. 2007;39(12):1477-1482. (Pubitemid 350191346)
7. Thomson W, Barton A, Ke X, et al. Rheumatoid arthritis association at 6q23. Nat Genet. 2007;39(12):1431-1433. (Pubitemid 350191348)
8. Trynka G, Zhernakova A, Romanos J, et al. Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut. 2009;58(8):1078-1083.
9. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009;206(5):981-989.
10. Chanudet E, Huang Y, Ichimura K, et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia. 2010;24(2):483-487.
11. Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer. 2008;47(1):1-7. (Pubitemid 350191458)
12. Novak U, Rinaldi A, Kwee I, et al. The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood. 2009;113(20):4918-4921.
13. Packham G. The role of NF-kappaB in lymphoid malignancies. Br J Haematol. 2008;143(1):3-15.
14. Hymowitz SG, Wertz IE. A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer. 2010;10(5):332-341.
15. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301-310. (Pubitemid 37328783)
16. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30(8):383-391.
17. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science. 2010;327(5969):1135- 1139.
18. Turer EE, Tavares RM, Mortier E, et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J Exp Med. 2008;205(2):451-464. (Pubitemid 351281609)
19. Vereecke L, Sze M, Guire CM, et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med. 2010;207(7):1513-1523.
20. Sasaki Y, Derudder E, Hobeika E, et al. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B-cell proliferation upon activation. Immunity. 2006;24(6):729-739. (Pubitemid 43867365)
21. Schmidt-Supprian M, Tian J, Ji H, et al. I kappa B kinase 2 deficiency in T cells leads to defects in priming, B cell help, germinal center reactions, and homeostatic expansion. J Immunol. 2004;173(3):1612-1619. (Pubitemid 38971591)
22. Schmidt-Supprian M, Rajewsky K. Vagaries of conditional gene targeting. Nat Immunol. 2007;8(7):665-668. (Pubitemid 46965339)
23. Fairfax KA, Kallies A, Nutt SL, Tarlinton DM. Plasma cell development: from B-cell subsets to long-term survival niches. Semin Immunol. 2008;20(1):49-58.
24. Guinamard R, Okigaki M, Schlessinger J, Ravetch JV. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol. 2000;1(1):31-36.
25. Allman D, Pillai S. Peripheral B-cell subsets. Curr Opin Immunol. 2008;20(2):149-157.
26. Casola S, Rajewsky K. B cell recruitment and selection in mouse GALT germinal centers. Curr Top Microbiol Immunol. 2006;308:155-171. (Pubitemid 47400301)
27. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev. 2008;224:201-214.
28. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol. 2004;4(4):386-391. (Pubitemid 38987066)
29. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med. 2006;203(3):553-561.
30. Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol. 2009;9(12):845-857.
31. Hiroi T, Yanagita M, Ohta N, Sakaue G, Kiyono H. IL-15 and IL-15 receptor selectively regulate differentiation of common mucosal immune system-independent B-1 cells for IgA responses. J Immunol. 2000;165(8):4329- 4337.
32. Cancro MP, Hao Y, Scholz JL, et al. B cells and aging: molecules and mechanisms. Trends Immunol. 2009;30(7):313-318.
33. Tsantikos E, Oracki SA, Quilici C, Anderson GP, Tarlinton DM, Hibbs ML. Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. J Immunol. 2010;184(3):1348-1360.
34. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830-1835.
35. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299(5609):1033-1036. (Pubitemid 36222922)
36. Abe J, Ueha S, Suzuki J, Tokano Y, Matsushima K, Ishikawa S. Increased Foxp3(+) CD4(+) regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus. Am J Pathol. 2008;173(6):1682-1692.
37. Tavares RM, Turer EE, Liu CL, et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity. 2010;33(2):181-191.
38. Shoenfeld Y, Toubi E. Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum. 2005;52(9):2599-2606. (Pubitemid 41369087)
39. Witte T. IgM antibodies against dsDNA in SLE. Clin Rev Allergy Immunol. 2008;34(3):345-347.
40. Font J, Cervera R, Lopez-Soto A, et al. Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations. Clin Rheumatol. 1989;8(4):475-483.
41. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22(5):347-352.